Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

Radiology. 2019 Nov;293(2):424-433. doi: 10.1148/radiol.2019190306. Epub 2019 Sep 24.

PMID:
31549947
2.

Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.

Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C, Weinstock-Guttman B.

Mult Scler Relat Disord. 2019 Nov;36:101388. doi: 10.1016/j.msard.2019.101388. Epub 2019 Sep 9.

PMID:
31525628
3.

Preserved network functional connectivity underlies cognitive reserve in multiple sclerosis.

Fuchs TA, Benedict RHB, Bartnik A, Choudhery S, Li X, Mallory M, Oship D, Yasin F, Ashton K, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Hum Brain Mapp. 2019 Dec 15;40(18):5231-5241. doi: 10.1002/hbm.24768. Epub 2019 Aug 24.

PMID:
31444887
4.

Plasma levels of protein C pathway proteins and brain magnetic resonance imaging volumes in multiple sclerosis.

Ziliotto N, Zivadinov R, Baroni M, Marchetti G, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Straudi S, Manfredini F, Ramanathan M, Bernardi F.

Eur J Neurol. 2020 Feb;27(2):235-243. doi: 10.1111/ene.14058. Epub 2019 Sep 8.

PMID:
31408242
5.

Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D.

Neurology. 2019 Aug 6;93(6):e611-e623. doi: 10.1212/WNL.0000000000007892. Epub 2019 Jul 8.

PMID:
31285398
6.

Salient Central Lesion Volume: A Standardized Novel Fully Automated Proxy for Brain FLAIR Lesion Volume in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Barnett MH, Wang C, Tomic D, Silva D, Zivadinov R.

J Neuroimaging. 2019 Sep;29(5):615-623. doi: 10.1111/jon.12650. Epub 2019 Jul 1.

PMID:
31259467
7.

Trait Conscientiousness predicts rate of brain atrophy in multiple sclerosis.

Fuchs TA, Benedict RH, Wilding G, Wojcik C, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zivadinov R, Dwyer MG.

Mult Scler. 2019 Jun 20:1352458519858605. doi: 10.1177/1352458519858605. [Epub ahead of print]

PMID:
31219390
8.

Aging and Brain Atrophy in Multiple Sclerosis.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10.

PMID:
31074192
9.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.

10.

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.

Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.

AJNR Am J Neuroradiol. 2019 Mar;40(3):446-452. doi: 10.3174/ajnr.A5987. Epub 2019 Feb 28.

PMID:
30819766
11.

Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.

Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R.

J Neurol. 2019 Apr;266(4):866-875. doi: 10.1007/s00415-019-09208-0. Epub 2019 Feb 13.

PMID:
30758665
12.

Are Plasma Levels of Vascular Adhesion Protein-1 Associated Both with Cerebral Microbleeds in Multiple Sclerosis and Intracerebral Haemorrhages in Stroke?

Ziliotto N, Zivadinov R, Jakimovski D, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Ramanathan M, Marchetti G, Bernardi F.

Thromb Haemost. 2019 Jan;119(1):175-178. doi: 10.1055/s-0038-1676346. Epub 2018 Dec 31.

PMID:
30597511
13.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

14.

Plasma levels of soluble NCAM in multiple sclerosis.

Ziliotto N, Zivadinov R, Jakimovski D, Baroni M, Tisato V, Secchiero P, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Bernardi F, Ramanathan M, Marchetti G.

J Neurol Sci. 2019 Jan 15;396:36-41. doi: 10.1016/j.jns.2018.10.023. Epub 2018 Oct 28.

PMID:
30412901
15.

Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?

Jakimovski D, Topolski M, Kimura K, Marr K, Gandhi S, Ramasamy DP, Bergsland N, Hagemeier J, Weinstock-Guttman B, Zivadinov R.

Clin Auton Res. 2019 Jun;29(3):329-338. doi: 10.1007/s10286-018-0555-6. Epub 2018 Aug 17.

PMID:
30120624
16.

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Eur J Neurol. 2019 Jan;26(1):87-e8. doi: 10.1111/ene.13769. Epub 2018 Sep 3.

PMID:
30103277
17.

Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage.

Zivadinov R, Polak P, Schweser F, Bergsland N, Hagemeier J, Dwyer MG, Ramasamy DP, Baker JG, Leddy JJ, Willer BS.

J Head Trauma Rehabil. 2018 Sep/Oct;33(5):E24-E32. doi: 10.1097/HTR.0000000000000422.

18.

Increased CCL18 plasma levels are associated with neurodegenerative MRI outcomes in multiple sclerosis patients.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Zamboni P, Marchetti G, Zivadinov R, Ramanathan M.

Mult Scler Relat Disord. 2018 Oct;25:37-42. doi: 10.1016/j.msard.2018.07.009. Epub 2018 Jul 7.

PMID:
30031282
19.

Atrophied Brain Lesion Volume: A New Imaging Biomarker in Multiple Sclerosis.

Dwyer MG, Bergsland N, Ramasamy DP, Jakimovski D, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2018 Sep;28(5):490-495. doi: 10.1111/jon.12527. Epub 2018 Jun 1.

PMID:
29856910
20.

Hemostasis biomarkers in multiple sclerosis.

Ziliotto N, Bernardi F, Jakimovski D, Baroni M, Marchetti G, Bergsland N, Ramasamy DP, Weinstock-Guttman B, Schweser F, Zamboni P, Ramanathan M, Zivadinov R.

Eur J Neurol. 2018 Sep;25(9):1169-1176. doi: 10.1111/ene.13681. Epub 2018 Jun 26.

PMID:
29758118
21.

Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.

Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 Apr 15;387:152-156. doi: 10.1016/j.jns.2018.02.023. Epub 2018 Feb 10.

PMID:
29571854
22.

Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis.

Zivadinov R, Ramasamy DP, Hagemeier J, Kolb C, Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Hojnacki D.

AJNR Am J Neuroradiol. 2018 Apr;39(4):642-647. doi: 10.3174/ajnr.A5541. Epub 2018 Feb 8.

23.

Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study.

Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B.

Mult Scler. 2017 Sep;23(10):1336-1345. doi: 10.1177/1352458516678083. Epub 2016 Nov 4.

PMID:
27811339
24.

Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study.

Zivadinov R, Ramasamy DP, Benedict RR, Polak P, Hagemeier J, Magnano C, Dwyer MG, Bergsland N, Bertolino N, Weinstock-Guttman B, Kolb C, Hojnacki D, Utriainen D, Haacke EM, Schweser F.

Radiology. 2016 Dec;281(3):884-895. Epub 2016 Jun 16.

PMID:
27308776
25.

Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.

Beggs CB, Magnano C, Belov P, Krawiecki J, Ramasamy DP, Hagemeier J, Zivadinov R.

PLoS One. 2016 May 2;11(5):e0153960. doi: 10.1371/journal.pone.0153960. eCollection 2016.

26.

Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.

Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B.

Eur J Neurol. 2016 Jun;23(6):1101-9. doi: 10.1111/ene.12992. Epub 2016 Mar 21.

PMID:
26998905
27.

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.

Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E, Horakova D.

Mult Scler. 2016 Nov;22(13):1709-1718. Epub 2016 Feb 16.

PMID:
26883943
28.

Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.

Weinstock-Guttman B, Hagemeier J, Kavak KS, Saini V, Patrick K, Ramasamy DP, Nadeem M, Carl E, Hojnacki D, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Sep;87(9):937-43. doi: 10.1136/jnnp-2015-312221. Epub 2016 Jan 18.

PMID:
26780938
29.

Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS.

Zivadinov R, Cerza N, Hagemeier J, Carl E, Badgett D, Ramasamy DP, Weinstock-Guttman B, Ramanathan M.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 7;3(1):e190. doi: 10.1212/NXI.0000000000000190. eCollection 2016 Feb.

30.

Immunological and short-term brain volume changes in relapsing forms of multiple sclerosis treated with interferon beta-1a subcutaneously three times weekly: an open-label two-arm trial.

Dwyer MG, Zivadinov R, Tao Y, Zhang X, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Weinstock-Guttman B, Hayward B, Dangond F, Markovic-Plese S.

BMC Neurol. 2015 Nov 11;15:232. doi: 10.1186/s12883-015-0488-9.

31.

Increased contrast enhancing lesion activity in relapsing-remitting multiple sclerosis migraine patients.

Graziano E, Hagemeier J, Weinstock-Guttman B, Ramasamy DP, Zivadinov R.

Neuroimage Clin. 2015 Aug 1;9:110-6. doi: 10.1016/j.nicl.2015.07.013. eCollection 2015.

32.

The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.

Zivadinov R, Dwyer MG, Ramasamy DP, Davis MD, Steinerman JR, Khan O.

J Neuroimaging. 2015 Nov-Dec;25(6):989-95. doi: 10.1111/jon.12293. Epub 2015 Sep 22.

33.

Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis.

Modica CM, Bergsland N, Dwyer MG, Ramasamy DP, Carl E, Zivadinov R, Benedict RH.

Mult Scler. 2016 Jan;22(1):36-42. doi: 10.1177/1352458515579443. Epub 2015 Apr 28.

PMID:
25921038
34.

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a.

Uher T, Horakova D, Kalincik T, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

Eur J Neurol. 2015 Jul;22(7):1113-23. doi: 10.1111/ene.12716. Epub 2015 Apr 22.

PMID:
25904020
35.

Dirty-Appearing White Matter in the Brain is Associated with Altered Cerebrospinal Fluid Pulsatility and Hypertension in Individuals without Neurologic Disease.

Beggs CB, Magnano C, Shepherd SJ, Belov P, Ramasamy DP, Hagemeier J, Zivadinov R.

J Neuroimaging. 2016 Jan-Feb;26(1):136-43. doi: 10.1111/jon.12249. Epub 2015 Apr 20.

PMID:
25893376
36.

White Matter Hyperintensities and Mild Cognitive Impairment in Parkinson's Disease.

Mak E, Dwyer MG, Ramasamy DP, Au WL, Tan LC, Zivadinov R, Kandiah N.

J Neuroimaging. 2015 Sep-Oct;25(5):754-60. doi: 10.1111/jon.12230. Epub 2015 Mar 5.

PMID:
25753576
37.

Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis.

Kappus N, Weinstock-Guttman B, Hagemeier J, Kennedy C, Melia R, Carl E, Ramasamy DP, Cherneva M, Durfee J, Bergsland N, Dwyer MG, Kolb C, Hojnacki D, Ramanathan M, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):181-7. doi: 10.1136/jnnp-2014-310051. Epub 2015 Feb 26.

PMID:
25722366
38.

Relationship between gray matter volume and cognitive learning in CIS patients on disease-modifying treatment.

Uher T, Benedict RH, Horakova D, Bergsland N, Dusankova JB, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

J Neurol Sci. 2014 Dec 15;347(1-2):229-34. doi: 10.1016/j.jns.2014.10.002. Epub 2014 Oct 8.

PMID:
25456460
39.

MRI correlates of disability progression in patients with CIS over 48 months.

Uher T, Horakova D, Bergsland N, Tyblova M, Ramasamy DP, Seidl Z, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

Neuroimage Clin. 2014 Sep 28;6:312-9. doi: 10.1016/j.nicl.2014.09.015. eCollection 2014.

40.

Prospective randomized trial of venous angioplasty in MS (PREMiSe).

Siddiqui AH, Zivadinov R, Benedict RH, Karmon Y, Yu J, Hartney ML, Marr KL, Valnarov V, Kennedy CL, Ramanathan M, Ramasamy DP, Dolic K, Hojnacki DW, Carl E, Levy EI, Hopkins LN, Weinstock-Guttman B.

Neurology. 2014 Jul 29;83(5):441-9. doi: 10.1212/WNL.0000000000000638. Epub 2014 Jun 27. Erratum in: Neurology. 2014 Aug 19;83(8):773.

41.

Longitudinal MRI and neuropsychological assessment of patients with clinically isolated syndrome.

Uher T, Blahova-Dusankova J, Horakova D, Bergsland N, Tyblova M, Benedict RH, Kalincik T, Ramasamy DP, Seidl Z, Hagermeier J, Vaneckova M, Krasensky J, Havrdova E, Zivadinov R.

J Neurol. 2014 Sep;261(9):1735-44. doi: 10.1007/s00415-014-7413-9. Epub 2014 Jun 22.

PMID:
24952618
42.

Serum lipoprotein composition and vitamin D metabolite levels in clinically isolated syndromes: Results from a multi-center study.

Browne RW, Weinstock-Guttman B, Zivadinov R, Horakova D, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Qu J, Havrdova E, Ramanathan M.

J Steroid Biochem Mol Biol. 2014 Sep;143:424-33. doi: 10.1016/j.jsbmb.2014.06.007. Epub 2014 Jun 17.

PMID:
24950029
43.

Effect of treatment with interferon beta-1a on changes in voxel-wise magnetization transfer ratio in normal appearing brain tissue and lesions of patients with relapsing-remitting multiple sclerosis: a 24-week, controlled pilot study.

Zivadinov R, Dwyer MG, Markovic-Plese S, Kennedy C, Bergsland N, Ramasamy DP, Durfee J, Hojnacki D, Hayward B, Dangond F, Weinstock-Guttman B.

PLoS One. 2014 Mar 13;9(3):e91098. doi: 10.1371/journal.pone.0091098. eCollection 2014.

44.

Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study.

Jacobsen C, Hagemeier J, Myhr KM, Nyland H, Lode K, Bergsland N, Ramasamy DP, Dalaker TO, Larsen JP, Farbu E, Zivadinov R.

J Neurol Neurosurg Psychiatry. 2014 Oct;85(10):1109-15. doi: 10.1136/jnnp-2013-306906. Epub 2014 Feb 19.

PMID:
24554101
45.

Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.

Browne RW, Weinstock-Guttman B, Horakova D, Zivadinov R, Bodziak ML, Tamaño-Blanco M, Badgett D, Tyblova M, Vaneckova M, Seidl Z, Krasensky J, Bergsland N, Ramasamy DP, Hagemeier J, Havrdova E, Ramanathan M.

J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):859-64. doi: 10.1136/jnnp-2013-307106. Epub 2014 Jan 27.

PMID:
24470599
46.

Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome.

Cappellani R, Bergsland N, Weinstock-Guttman B, Kennedy C, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Patti F, Zivadinov R.

J Neurol Sci. 2014 Mar 15;338(1-2):128-34. doi: 10.1016/j.jns.2013.12.031. Epub 2013 Dec 31.

PMID:
24423584
47.

Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients.

Gabelic T, Weinstock-Guttman B, Melia R, Lincoff N, Masud MW, Kennedy C, Brinar V, Ramasamy DP, Carl E, Bergsland N, Ramanathan M, Zivadinov R.

Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S49-54. doi: 10.1016/j.clineuro.2013.09.021.

PMID:
24321155
48.

Development of gray matter atrophy in relapsing-remitting multiple sclerosis is not gender dependent: results of a 5-year follow-up study.

Dolezal O, Gabelic T, Horakova D, Bergsland N, Dwyer MG, Seidl Z, Krasensky J, Ramasamy DP, Vaneckova M, Havrdova E, Zivadinov R.

Clin Neurol Neurosurg. 2013 Dec;115 Suppl 1:S42-8. doi: 10.1016/j.clineuro.2013.09.020.

PMID:
24321154
49.

Subcortical deep gray matter pathology in patients with multiple sclerosis is associated with white matter lesion burden and atrophy but not with cortical atrophy: a diffusion tensor MRI study.

Cappellani R, Bergsland N, Weinstock-Guttman B, Kennedy C, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Patti F, Zivadinov R.

AJNR Am J Neuroradiol. 2014 May;35(5):912-9. doi: 10.3174/ajnr.A3788. Epub 2013 Dec 12.

50.

Jugular venous reflux and white matter abnormalities in Alzheimer's disease: a pilot study.

Chung CP, Beggs C, Wang PN, Bergsland N, Shepherd S, Cheng CY, Ramasamy DP, Dwyer MG, Hu HH, Zivadinov R.

J Alzheimers Dis. 2014;39(3):601-9. doi: 10.3233/JAD-131112.

PMID:
24217278

Supplemental Content

Loading ...
Support Center